China can offer global clinical development programs access to large patient populations, early efficacy signals and a potentially more capital-efficient path to proof of concept. But population size alone is not enough. Sponsors must determine whether China-generated evidence answers the right clinical question for the intended treatment population, accounting for epidemiology, standards of care, diagnostic pathways, concomitant medications and regional consistency in study endpoints.
The right development model depends on the decision the study must support. A China-only study may address a defined early-development question or China-focused objective. A multiregional clinical trial can coordinate a global evidence package and accelerate recruitment, fundraising or licensing milestones. A sequenced approach can begin in China to establish an early signal before global expansion, or add China later when a larger patient pool is needed.
Success also requires validated recruitment pathways and early planning. Site-level feasibility should assess eligibility criteria, prior therapies, competing trials, treatment options, investigator priorities, referral networks and site capacity. Considering China early does not require an early commitment, but it can preserve regulatory flexibility, reduce duplicated work and keep development options open. This conversation explores how local expertise, integrated governance and global accountability can turn China’s potential into an executable clinical strategy.